Atopic Dermatitis Drug Market Strategic Assessment And Forecast 2018-2026
Atopic dermatitis,
also known as eczema, is a condition in which skin becomes dry,
itchy, and inflamed, which leads to redness, swelling, scaling, and
crusting. Atopic dermatitis is commonly found in children under
one year. The exact cause of atopic dermatitis is undiscovered, but
it is believed that it includes genetics, environmental exposure,
immune system dysfunction, and problem with skin permeability. Dry
climate is also a major cause of atopic dermatitis. This disease is
non-contagious and easily diagnosed with signs and symptoms such as
swelling and redness of skin. Many people with atopic dermatitis
develop asthma and hay fever. Atopic dermatitis treatment involves
photo therapy, steroid pills, calcineurin inhibitors ointment,
biologic agents such as immunologic, monoclonal antibody, and dietary
changes in case of food allergy.
Request For A
Sample Copy Of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/712
Topical
steroids and development of new drugs fuel the atopic dermatitis drug
market
Atopic dermatitis
treatment majorly relies on topical steroids and hence the segment
holds the largest market share. A lukewarm bath followed by the
application of moisturizer helps in the treatment of atopic
dermatitis. Immunomodulators and pimecrolimus are also used for the
treatment of atopic dermatitis. According to the American Academy of
Dermatology, in 2016, there were around 28 million people of all age
groups affected by atopic dermatitis in the U.S. The expected launch
of dupilumab, monoclonal antibody developed by Sanofi and Regeneron
Pharmaceuticals Inc. in 2017, which is approved by FDA for the
treatment of atopic dermatitis plays a major role in the treatment of
the disease and supports the growth of atopic dermatitis drug market.
Atopic
Dermatitis Drug Market Taxonomy
By End User;
-
Hospitals
-
Clinics
-
Research Labs
By Route of
Administration;
-
Injectable
-
Oral
-
Topical
By Therapy;
-
Photo Therapy
-
Directed Therapy
Developed
regions support the growth of atopic dermatitis drug market
On the basis of
geography, the global atopic dermatitis drug market is segmented into
North America, Latin America, Europe, Asia Pacific, and Middle East &
Africa. North America dominates the atopic dermatitis drug market due
to increasing number of atopic dermatitis cases and high R&D
investment for the development of atopic dermatitis drug. The
increase in food and skin allergies raised the atopic dermatitis
cases in infants, which in turn fuels the atopic dermatitis drug
market growth.
Key Players
in the Global Atopic Dermatitis Drug Market
Major players in the
market use different strategies such as mergers and acquisitions in
order to acquire high market share and attain a competitive edge. In
2016, Novartis AG acquired Ziarco, which adds oral atopic dermatitis
drug to its product pipeline. Pfizer acquired Anacor Pharmaceuticals
in 2016 allowing access to non-steroidal topical gel, crisaborole,
approved by FDA for atopic dermatitis treatment. Some of the key
players in the market are Bayer Healthcare, Valent Pharmaceutical
Inc., Astellas Pharma Inc., Meda AB, and Novartis AG.
Click To Read More On Atopic
Dermatitis Drug Market
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Comments
Post a Comment